AZN.L AstraZeneca PLC
Company Analysis
Latest News
🟢 AstraZeneca is trading 3.14% up today amid healthcare gains after UnitedHealth’s strong Q3 earnings
AstraZeneca is trading at £12,270.00, up 3.14%, on October 14, 2026, as healthcare stocks rose after investors responded to UnitedHealth’s...
AstraZeneca Wins EU Nod for Trixeo, First Single-Inhaler Triple Asthma Therapy
AstraZeneca has received European Union approval for Trixeo Aerosphere as maintenance treatment for asthma in patients aged 12 and older whose symptoms are not...
AstraZeneca Secures FDA Priority Review for Imfinzi Bladder Cancer Combo
AstraZeneca said the U.S. Food and Drug Administration (FDA) accepted and granted Priority Review to its supplemental Biologics License Application (sBLA) for...
AstraZeneca wins FDA Priority Review for rare bone disease treatment
AstraZeneca announced the U.S. Food and Drug Administration accepted and granted Priority Review for efzimfotase alfa. This investigational enzyme replacement...
AstraZeneca’s Enhertu wins NHS recommendation, following new pricing agreement
AstraZeneca and Daiichi Sankyo’s breast cancer drug, Enhertu, received a recommendation for routine NHS use in England. The National Institute for Health and...
🟢 AstraZeneca is trading 3.37% up today after reported $15 billion ivonescimab licensing talks
AstraZeneca is trading £12,102 (+3.37%) after reports on September 14, 2026, that it is negotiating a potential ivonescimab licensing partnership with Summit...
AstraZeneca, Amgen Lung Cancer Combo Boosts Survival in Phase III Trial
AstraZeneca PLC and Amgen Inc. announced positive results from a late-stage clinical trial for a combination lung cancer treatment. The study tested Imdelltra...
AstraZeneca’s Tezspire succeeds in late-stage trial, boosting pipeline after setbacks
AstraZeneca and partner Amgen reported positive Phase III CROSSING trial results for Tezspire. The drug met all primary endpoints for treating eosinophilic...
🟢 AstraZeneca is trading 3.02% up today amid €2.55 billion bond pricing
AstraZeneca is trading at £12476.00 (+3.02%) after reaching its alert threshold during the August 25, 2026 session; no confirmed company-specific catalyst has...
AstraZeneca Lung Cancer Drugs Beat Standard Care in Dual Phase III Trials
AstraZeneca reported positive high-level results from two separate Phase III lung cancer trials. The SAFFRON trial showed that Tagrisso combined with Orpathys...
🟢 AstraZeneca is trading 3.1% up today after rebounding from Bristol Myers Squibb merger selloff
AstraZeneca is trading 3.1% up today at £12,106, partially recovering from a sharp decline triggered by merger speculation with Bristol Myers Squibb. • Shares...
🔴 AstraZeneca is trading 9% down today on reports of a risky $400 billion merger with Bristol Myers Squibb
AstraZeneca is trading approximately 9% down at £11,500 following reports of preliminary merger talks with Bristol Myers Squibb for a potential $400 billion...
🔴 AstraZeneca is trading 6.1% down today on reported merger talks with Bristol Myers Squibb
AstraZeneca is trading 6.1% down at £11864 following reports of preliminary merger talks with Bristol Myers Squibb to create a $400 billion pharmaceutical...
AstraZeneca pursues Bristol Myers merger, creating $400 billion pharma giant
AstraZeneca and Bristol Myers Squibb held preliminary talks regarding a potential merger. The combined entity would reach a market value approaching $400...